Somatostatin analogues: Treatment for portal hypertension?
Article first published online: 6 DEC 2005
Copyright © 1986 American Association for the Study of Liver Diseases
Volume 6, Issue 6, pages 1432–1434, November/December 1986
How to Cite
Blei, A. T. (1986), Somatostatin analogues: Treatment for portal hypertension?. Hepatology, 6: 1432–1434. doi: 10.1002/hep.1840060641
- Issue published online: 6 DEC 2005
- Article first published online: 6 DEC 2005
The effects of a somatostatin analogue, SMS 201-995 on hepatic haemodynamics were studied in rats with dimethylnitrosamine-induced cirrhosis. An intravenous infusion of 1, 2 or 4 μg kg−1 body wt h−1 SMS 201-995 produced a rapid and sustained decrease in portal pressure, portal venous flow and liver blood flow without significantly altering arterial blood pressure or pulse. The reductions in portal pressure, portal venous flow and liver blood were accompanied by an increase in splanchnic vascular resistance. Portal venous resistance was not affected. Subcutaneous injection of 2 μg kg−1 body wt SMS 201-995 produced a gradual decrease in portal pressure, the maximum reduction occurring 18 min after administration. This reduction in portal pressure was sustained for a further 20 min. The results suggest that SMS 201-995 may be of value in the control of bleeding oesophageal varices. Furthermore, the prolonged duration of action of SMS 201-995 following its subcutaneous administration suggests that the analogue may be useful in the long-term management of portal hypertension in patients with cirrhosis.